Alliancebernstein L.P. Has $169.14 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Alliancebernstein L.P. reduced its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 6,375,369 shares of the biopharmaceutical company's stock after selling 249,600 shares during the period. Alliancebernstein L.P. owned approximately 0.11% of Pfizer worth $169,139,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. PSI Advisors LLC lifted its stake in Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after acquiring an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC lifted its position in shares of Pfizer by 1.0% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after purchasing an additional 391 shares in the last quarter. D Orazio & Associates Inc. lifted its position in shares of Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock worth $200,000 after purchasing an additional 391 shares in the last quarter. Lipe & Dalton boosted its holdings in Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC grew its position in Pfizer by 2.2% in the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock valued at $499,000 after purchasing an additional 401 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Remove Ads

Pfizer Stock Performance

Shares of Pfizer stock traded down $0.41 on Thursday, hitting $24.30. The stock had a trading volume of 53,412,700 shares, compared to its average volume of 39,300,356. The stock has a market cap of $137.79 billion, a price-to-earnings ratio of 17.23, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The business's 50 day moving average is $25.98 and its two-hundred day moving average is $26.83. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.26 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the previous year, the business posted $0.10 earnings per share. Pfizer's quarterly revenue was up 24.7% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Bank of America reissued a "neutral" rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Finally, Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.